🏢 TPEX | Building Intelligence and Optimization Solutions
At TPEX, we're passionate about revolutionizing building processes, optimizing functionalities, and taking control of day-to-day building operations. Our mission is to make buildings smarter by connecting them to our cutting-edge Building Intelligence Platform.
🏗️ What We Do:
We specialize in analyzing building processes, optimizing functionalities, and ensuring efficient operations based on real-time data, analysis, and logic. By connecting buildings to our platform, we drive efficiency, enhance ESG ratings, and elevate property values, contributing to a more sustainable future.
🏆 Our Mission: Turning Buildings into High Performance Buildings
High Performance Buildings, to us, are efficient, healthy, intelligent, and optimized. They produce zero waste, offer high indoor air quality, leverage cutting-edge technology, and ensure operations are optimized every single day to support the primary processes of their occupants.
💡 Why We Do It:
The world faces scarcity of resources and substantial CO2 emissions. Real estate is a major consumer and waster of energy and water. Inefficient operational processes lead to discomfort and loss of time, impacting users' well-being. We strive to rectify these issues, ensuring a more sustainable and efficient built environment.
🌍 Our Approach:
By embracing ongoing digitalization, IoT, AI, and enhanced data analysis tools, we offer solutions that enable buildings to function efficiently and autonomously. The adoption of digital transitions in building performance improvement is crucial in achieving climate goals and securing a sustainable future.
🤝 Connect with Us:
Join us on our journey to transform buildings and create a more sustainable future. Follow our page for the latest updates, insights, and job opportunities in the realm of building intelligence and optimization.
📧 Contact Us:
For partnerships, inquiries, or career, get in touch with us at info@tpex.com
Type 1 conventional dendritic cells maintain and guide the differentiation of precursors of exhausted T cells in distinct cellular niches ScienceDirect.com
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, pha The Lancet
Sign up for a free account. No credit card required. Up to 10 free credits.
Search the #1 Contact Database
Get contact details of over 750M+ profiles across 60M companies – all with industry-leading accuracy. Sales Navigator and Recruiter users, try out our Email Finder Extension.
Use our AI-Powered Email Finder
Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.